
Cancer immunotherapies by design, and in development.
Our pipeline
Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.
Preclinical
Phase 1
Phase 2a
Randomized
Registration-directed
EOS-448
+ dostarlimab | Solid Tumors
Phase 1, dosing
+ dostarlimab | 1L NSCLC PDL1high
Registration-directed, non-dosing
+ dostarlimab | HNSCC
Registration-directed, non-dosing
+ dostarlimab | Undisclosed
Registration-directed, non-dosing
+ dostarlimab + CD96 | Solid Tumors
Phase 1, non-dosing
+ dostarlimab + Inupadenant | Solid Tumors
Phase 1, non-dosing
+ Inupadenant | PD-1 Resistant Melanoma
Phase 1, dosing
Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma
Phase 2a, dosing
Inupadenant
Monotherapy | Evaluating Patient and Indication Selection Biomarkers
Phase 2, dosing
+ pembrolizumab | PD-1 Resistant Melanoma
Phase 2, dosing
+ chemotherapy | Post-IO mNSCLC
Randomized, non-dosing
EOS-984
IND Enabling Studies
Preclinical, dosing
Studies with dark backgrounds are dosing patients. Studies with light backgrounds have not yet dosed patients.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.
We bring our deep understanding of the tumor microenvironment and immunosuppressive pathways to design new products and improve the clinical benefit of oncology therapies.